Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

  |  Issue: February 2022  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Highlights of prescribing information: Actemra (tocilizumab). U.S. Food & Drug Administration. 2021 Mar 4.
  2. Ahn S, Oh J, Heo H, et al. Flare after switching from intravenous tocilizumab to subcutaneous formulation in patients with rheumatoid arthritis [abstract: 0836]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
  3. BLA approval. BL 125276. (Tocilizumab (Actemra): FDA approval letter.) U.S. Food & Drug Administration. 2010 Jan 8.
  4. BLA approval. BLA 125472/0. (Tocilizumab (Actemra) solution for subcutaneous injection: FDA approval letter.) 2013 Oct 21.

Related Articles